QF-PCR in pregnancy loss analysis
QF-PCR in pregnancy loss samples by Dr Helen White
Traditionally, karyotype analysis of pregnancy loss samples has been the gold standard method for evaluating the genetic cause of pregnancy loss. However, this approach is labour intensive, expensive, requires highly trained technical staff and is often unsuccessful due to the high tissue culture failure rate. Several alternative methodologies to karyotype analysis have been used to investigate genetic abnormalities in pregnancy loss. The QF-PCR method is one of them that is now used more widely for the analysis of pregnancy loss samples..
- Alternative technologies used to investigate genetic abnormalities in pregnancy loss.
- How QF-PCR of short tandem repeats (STR) is used in analysis of pregnancy loss samples.
- Special considerations when working with QF-PCR.
Get access to the paper by filling out the form below
QF-PCR in pregnancy loss analysis
QF-PCR in pregnancy loss samples by Dr Helen White
Traditionally, karyotype analysis of pregnancy loss samples has been the gold standard method for evaluating the genetic cause of pregnancy loss. However, this approach is labour intensive, expensive, requires highly trained technical staff and is often unsuccessful due to the high tissue culture failure rate. Several alternative methodologies to karyotype analysis have been used to investigate genetic abnormalities in pregnancy loss. The QF-PCR method is one of them that is now used more widely for the analysis of pregnancy loss samples..
- Alternative technologies used to investigate genetic abnormalities in pregnancy loss.
- How QF-PCR of short tandem repeats (STR) is used in analysis of pregnancy loss samples.
- Special considerations when working with QF-PCR.
Related content
View allDevyser Diagnostics AB publishes quarterly report for the period April to June 2024
“Devyser continued to report high sales growth in the second quarter. Organic growth compared with...
Read More
Devyser wins tender in Italy for its cystic fibrosis NGS test worth up to 5.9 million SEK
Read More
Devyser wins tender in Sweden for Thalassemia NGS testing worth up to 8.4 million SEK
Read More